News
Novo's Wegovy has lost market share to Eli Lilly's Zepbound, and a new head-to-head study found that Zepbound patients lost ...
20h
Zacks Investment Research on MSNCI's Unit Unveils Offering to Expand Access to GLP-1 MedicationsThe health services arm of The Cigna Group CI, Evernorth, recently introduced a pharmacy benefit offering designed to enhance ...
As demand for GLP-1 weight-loss medications like Wegovy and Zepbound continues to grow in the United States, so do questions about their affordability.
Hims & Hers has delivered strong results and partnerships, but recent Cigna/Novo Nordisk news increases competitive risk and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results